目的 觀察石斛破壁草本聯(lián)合奧美拉唑治療慢性萎縮性胃炎的臨床療效。方法 回顧性選取2020年1月—2021年12月淮南朝陽醫(yī)院收治的112例幽門螺桿菌陽性的慢性萎縮性胃炎患者，根據(jù)治療方案不同分為對照組和試驗組，每組各56例。對照組采用基礎(chǔ)治療方案（口服奧美拉唑腸溶膠囊、阿莫西林膠囊和克拉霉素緩釋片）治療；試驗組在對照組基礎(chǔ)上加用石斛破壁草本，沖泡服用，每次2袋，每天3次。兩組患者治療療程均為1個月。采用世界衛(wèi)生組織生活質(zhì)量量表（WHOQOL-100）評估患者治療前和治療后的生活質(zhì)量，采取酶聯(lián)免疫吸附法（ELISA）檢測兩組患者治療前后炎癥因子C-反應(yīng)蛋白（CRP）、白細胞介素-1β（IL-1β）、腫瘤壞死因子α（TNF-α）及血清胃蛋白酶原Ⅰ（PG I）、血清胃蛋白酶原Ⅱ（PGⅡ）和胃泌素-17（G17）水平。觀察記錄兩組患者治療總有效率及不良反應(yīng)情況。結(jié)果 治療前，兩組患者WHOQOL-100評分比較，差異無統(tǒng)計學(xué)意義（P＞0.05）；治療后，兩組患者WHOQOL-100評分均顯著高于治療前（P＜0.01），治療后試驗組WHOQOL-100評分顯著高于對照組（P＜0.01）。對照組和試驗組總有效率分別為85.71%和96.42%，兩組比較差異無統(tǒng)計學(xué)意義（P＞0.05）；試驗組總顯效率為78.57%，顯著高于對照組的64.28%（P＜0.01）。治療前，兩組患者CRP、TNF-α和IL-1β水平比較差異無統(tǒng)計學(xué)意義（P＞0.05）；治療后，兩組患者CRP、TNF-α和IL-1β水平均較治療前顯著降低（P＜0.01），且治療后試驗組各炎性因子水平均低于對照組（P＜0.01）。治療前，兩組患者PGⅠ、PGⅡ和G17水平比較差異無統(tǒng)計學(xué)意義（P＞0.05）；治療后兩組患者PGⅡ和G17水平較治療前顯著降低（P＜0.01），PGⅠ水平較治療前顯著升高（P＜0.01）；治療后，試驗組PGⅡ和G17水平顯著低于對照組（P＜0.05），PGⅠ水平顯著高于對照組（P＜0.01）。治療前兩組患者中醫(yī)證候評分比較差異無統(tǒng)計學(xué)意義（P＞0.05）；治療后兩組患者中醫(yī)證候評分均較治療前顯著降低（P＜0.01），且治療后試驗組中醫(yī)證候評分顯著低于對照組（P＜0.05）。兩組患者治療過程中不良反應(yīng)發(fā)生率無顯著差異，且不良反應(yīng)發(fā)生率較低。結(jié)論 西醫(yī)常規(guī)治療聯(lián)合石斛破壁草本治療慢性萎縮性胃炎臨床效果顯著，安全性好。

Objective To observe the clinical efficacy of breaking cell wall herb of Dendrobii Caulis combined with omeprazole in treatment of chronic atrophic gastritis. Methods A total of 112 patients with chronic atrophic gastritis and positive Helicobacter pylori treated in Huainan Chaoyang Hospital from January 2020—December 2021 were selected retrospectively. Patients were divided into control group and experimental group according to different treatment schemes, with 56 cases in each group. Patients in the control group were treated with basic treatment scheme (oral Omeprazole Enteric Coated Capsule, Amoxil Capsule and Clarithromycin Sustained-Release Tablets). On the basis of the control group, Patients in the experimental group were added breaking cell wall herb of Dendrobii Caulis, brewed and taken, two bags each time, three times a day. The treatment course of both groups was one month. The World Health Organization Quality of life scale (WHOQOL-100) was used to evaluate the quality of life of patients before and after treatment. The inflammatory factors C-reactive protein (CRP), interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) were detected by enzyme-linked immunosorbent assay (ELISA), and the levels of serum pepsinogen Ⅰ (PGⅠ), serum pepsinogen Ⅱ (PGⅡ) and gastrin-17 (G17) were detected by ELISA method. The total effective rate and adverse reactions of two groups were observed and recorded. Results Before treatment, there was no significant difference in WHOQOL-100 score between two groups (P>0.05). After treatment, the WHOQOL-100 score of two groups was significantly higher than that before treatment (P<0.01). Compared with the control group, the WHOQOL-100 score of the experimental group was significantly higher than that of the control group (P<0.01). The total effective rates of the control group and the experimental group were 85.71% and 96.42% respectively. There was no significant difference between two groups (P>0.05). The total effective rate of the experimental group was 78.57%, which was significantly higher than 64.28% of the control group (P<0.01). Before treatment, there was no significant difference in level of CRP, TNF-α and IL-1β in two groups (P>0.05). After treatment, the levels of CRP, TNF-α and IL-1β in two groups were significantly lower than those before treatment (P<0.01), and the levels of inflammatory factors in the experimental group were lower than those in the control group (P<0.01). Before treatment, there was no significant difference in the levels of PGⅠ, PGⅡ and G17 between two groups (P>0.05). After treatment, the levels of PGⅡ and G17 in two groups were significantly lower than those before treatment (P<0.01), and the level of PGⅠ was significantly higher than that before treatment (P<0.01). After treatment, the levels of PGⅡ and G17 in the experimental group were significantly lower than those in the control group (P<0.05), and the level of PGⅠ was significantly higher than those in the control group (P<0.01). There was no significant difference in TCM syndrome scores between two groups before treatment (P>0.05). After treatment, the TCM syndrome scores of two groups were significantly lower than those before treatment (P<0.01), and the TCM syndrome scores of the experimental group were significantly lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between two groups, and the incidence of adverse reactions was low. Conclusion Breaking cell wall herb of Dendrobii Caulis combined with the conventional treatment of Western medicine is effective and safe in treatment of chronic atrophic gastritis.

R975